메뉴 건너뛰기
New England Journal of Medicine
Volumn 364, Issue 26, 2011, Pages 2547-2548
Been there, not done that - Melanoma in the age of molecular therapy
Author keywords

[No Author keywords available]
Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; CYTOTOXIC AGENT; DACARBAZINE; ESTROGEN RECEPTOR; GLUTAMIC ACID; INTERLEUKIN 2; SORAFENIB; TAMOXIFEN; VALINE; VEMURAFENIB;
EID: 79959791242     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1105792     Document Type: Editorial
Times cited : (12)
References (10)
  • 1
    • 0017195219 scopus 로고
    • Oestrogen receptors in human malignant melanoma
    • Fisher RI, Neifeld JP, Lippman ME. Oestrogen receptors in human malignant melanoma. Lancet 1976;2:337-9.
    • (1976) Lancet , vol.2 , pp. 337-339
    • Fisher, R.I.1    Neifeld, J.P.2    Lippman, M.E.3
  • 2
    • 0026625695 scopus 로고
    • Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen
    • Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992;327:516-23.
    • (1992) N Engl J Med , vol.327 , pp. 516-523
    • Cocconi, G.1    Bella, M.2    Calabresi, F.3
  • 3
    • 0036654443 scopus 로고    scopus 로고
    • A genome-based strategy uncovers frequent BRAF mutations in melanoma
    • DOI 10.1016/S1535-6108(02)00089-2
    • Pollock PM, Meltzer PS. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2002;2:5-7. (Pubitemid 41043982)
    • (2002) Cancer Cell , vol.2 , Issue.1 , pp. 5-7
    • Pollock, P.M.1    Meltzer, P.S.2
  • 4
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
    • (2010) N Engl J Med , vol.363 , pp. 809-819
    • Flaherty, K.T.1    Puzanov, I.2    Kim, K.B.3
  • 5
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
    • (2011) N Engl J Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 7
    • 77949732073 scopus 로고    scopus 로고
    • RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    • Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30.
    • (2010) Nature , vol.464 , pp. 427-430
    • Poulikakos, P.I.1    Zhang, C.2    Bollag, G.3    Shokat, K.M.4    Rosen, N.5
  • 8
    • 79951961755 scopus 로고    scopus 로고
    • Resistance to BRAF inhibition in melanomas
    • Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011;364:772-4.
    • (2011) N Engl J Med , vol.364 , pp. 772-774
    • Solit, D.B.1    Rosen, N.2
  • 9
    • 77954373338 scopus 로고    scopus 로고
    • Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function
    • Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010;70:5213-9.
    • (2010) Cancer Res , vol.70 , pp. 5213-5219
    • Boni, A.1    Cogdill, A.P.2    Dang, P.3
  • 10
    • 78650051587 scopus 로고    scopus 로고
    • Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin
    • Shukla A, Hillegass JM, MacPherson MB, et al. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer 2010;9:314.
    • (2010) Mol Cancer , vol.9 , pp. 314
    • Shukla, A.1    Hillegass, J.M.2    MacPherson, M.B.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.